Ochi S, et al. - A retrospective cohort study was conducted to compare rheumatoid arthritis (RA) individuals with insensitivity and those with a poor response to initial treatment with tumour necrosis factor inhibitors (TNFis), which are the most frequently used bDMARDs. Researchers conducted this study to use clinical data from the FIRST registry. Between August 2003 to May 2019, bDMARD-naïve RA patients treated with tumour necrosis factor inhibitors (TNFis) were involved and classified into three groups: TNFi insensitivity, poor response to TNFis and controls. Among the recruited individuals, 94 were classified in the insensitivity, 604 in the poor response and 915 in the control. It was considered that poor and insensitivity to bDMARDs should be evaluated separately to fully illustrate the aetiology of, and risk factors for, bDMARD refractoriness in future research.